Duke John D 4

4 · HARVARD BIOSCIENCE INC · Filed Mar 17, 2026

AI-generated summary of this filing

Updated Mar 17, 2026

Harvard Bioscience (HBIO) CEO John D. Duke Buys 5,000 Shares

What Happened

John D. Duke, CEO of Harvard Bioscience, bought 5,000 shares in an open-market purchase on March 16, 2026 at $5.01 per share, for a total cash outlay of $25,050. This was a purchase (acquisition) rather than a sale.

Key Details

Transaction date and price: 2026-03-16, 5,000 shares at $5.01 each.
Transaction type/code: Open-market purchase (P).
Cash value: $25,050.
Shares owned after transaction: Not stated in the filing.
Footnote highlights:
- F1: The filing also references (a) this 5,000-share purchase, (b) an award of 50,000 time‑based RSUs vesting in three equal installments on August 8, 2026, 2027 and 2028, and (c) an award of 50,000 performance‑based RSUs that vest based on relative total shareholder return vs. the Russell 2000 measured from August 8, 2025 to the earlier of July 30, 2028 or a change of control. The reported target for the performance RSUs is 50,000; the maximum payout is 150% of that amount.
- F2: A 10-for-1 reverse stock split on March 13, 2026 reduced previously reported RSU counts (e.g., 500,000 → 50,000) and the RSU figures in F1 reflect that adjustment.
Filing timeliness: Form 4 filed on 2026-03-17 for the March 16 transaction — appears timely (Form 4s are normally due within two business days).

Context

Purchases by executives can be taken by investors as a modest bullish signal because the insider is adding to holdings; the amount here ($25k) is relatively small.
The RSU awards referenced are grants/awards, not immediate transferable shares; time‑based RSUs vest on set dates and performance RSUs only vest if TSR targets vs. the Russell 2000 are met (with potential upside to 150% of target).

Form 4

Period: 2026-03-16

DirectorChief Executive Officer

Transactions

Footnotes (2)

[F1]Includes (a) 5,000 shares of common stock purchased on March 16, 2026, (b) an award of 50,000 restricted stock units (RSUs) that will vest in three equal installments on August 8, 2026, 2027 and 2028, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person and (c) an award of 50,000 RSUs with performance based vesting conditions. These RSUs will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from August 8, 2025 to the earlier of (i) July 30, 2028, and (ii) the date of a change of control, measured relative to the Russell2000 index, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these RSUs that may be earned is reported above; the maximum amount is 150% of the number reported.
[F2]On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 50,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 500,000 restricted stock units and the 50,000 restricted stock units referenced in Footnote 1(c) were previously reported as covering 500,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Signature

/s/ John D Duke|2026-03-17

1 file